ESR1, estrogen receptor 1, 2099

N. diseases: 1101; N. variants: 185
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Immunhistochemistry profiling of human endometrial cancer tissue biopsies identified epithelial cells co-expressing ERβ5 and ERα in stage I endometrial adenocarcinomas and post menopausal endometrium. 31778358 2020
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE There was a weak but statistically significant negative correlation between immunoreactivity of GPR30 and that of ER in cervical AIS and adenocarcinoma lesions (Spearman's correlation, r=-0.324, p=0.017). 31483053 2019
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE We examined this interplay and response to mTOR inhibition using ERα+ adenocarcinomas from NRL-PRL females in combination with Col1a1<sup>tmJae/+</sup> (mCol1a1) mice, which accumulate collagen-I around growing tumors. 29935374 2018
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE The most common breast cancer type was adenocarcinomas (59.1%) and half of the breast cancers were hormone sensitive, with estrogen receptor positive status in 10 of 19 tested and progesterone receptor positive status in 5 of 14 tested. 30087072 2018
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE Cervical adenocarcinomas are believed to lose estrogen response on the basis of no expression of a nuclear estrogen receptor such as ERα in clinical pathology. 30227306 2018
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Calretinin and cytokeratin 5 were used for reactive mesothelial cells and Wilms tumor 1, thyroid transcription factor 1, CDX2, and estrogen receptor were used to confirm the adenocarcinoma cells. 28862203 2018
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE A small subset of pulmonary adenocarcinomas shows immunoreactivity for ER clones 6F11 and 1D5 in FNA samples (18.2% and 9.1%, respectively). 29465823 2018
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE E-cadherin correlated with Bak and Bcl-xL in ER-positive adenocarcinomas (p =  .002, r = 0.382 and p <.001, r = 0.439, respectively) but not in ER-negative tumors. 28937296 2018
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Conditional expression of Ki-Ras<sup>G12V</sup> in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ERα)-positive adenocarcinoma. 28745321 2017
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Some studies have shown that activation of estrogen and estrogen receptor α or β (ERα/β) promote adenocarcinoma. 25692143 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE The objective was to characterize and associate the receptor reactivities of fibroblastic growth factor (FGF)-2, FGF-7, FGF-8, epidermal growth factor (EGF), α-actin and vimentin in relation to the androgen receptor (AR), α and β estrogen receptors (ERα and ERβ), and prolactin receptor in the prostate of elderly men showing low- and high-grade adenocarcinoma. 23362007 2013
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Most (90%) of the endometrial adenocarcinomas were positive for vimentin and estrogen receptor, all were negative for HPV, and 97% were negative for carcinoembryonic antigen. 23318908 2013
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE Our results indicate that in patients with grade G3 adenocarcinoma, the expression of AT1-R significantly decreased in comparison with G1 patients (p = 0.034), but the level of ERα was the highest in G2 and the lowest in G3. 22170435 2012
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE Such EGFR mutations are frequently found in adenocarcinoma with a strong expression of estrogen receptor (ER) beta, which has been shown to correlate with a favorable prognosis for the patients with EGFR mutations. 20615575 2011
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Thus, we examined the expression of PGRMC1 and PGRMC2 mRNA by relative quantitative PCR (RelqPCR) and determined whether transcript levels correlate with age, breast cancer staging, estrogen receptor alpha (ERα) status, and other morphometric features routinely used during the pathological examination of breast ductal adenocarcinomas. 20655063 2011
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group CTD_human ESR1 gene multiple copies were confirmed in 13/60 (21.6%) breast adenocarcinomas, but high amplification only in 8/13 (62.8%). 20458558 2011
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation group BEFREE ESR1 gene multiple copies were confirmed in 13/60 (21.6%) breast adenocarcinomas, but high amplification only in 8/13 (62.8%). 20458558 2011
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas. 20534993 2010
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE Immuno-histochemical examination of the expression of TRPM8 channels in human breast tissues revealed an over-expression of TRPM8 in breast adenocarcinomas, which is correlated with estrogen receptor positive (ER+) status of the tumours. 20482834 2010
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Human estrogen receptor alpha is highly homologous to estrogen receptor beta and consequently, antibodies used to detect estrogen receptor alpha in breast carcinomas may detect estrogen receptor beta in pulmonary adenocarcinomas. 19875957 2010
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE Estrogen receptor alpha nuclear expression significantly correlated with adenocarcinoma histology, female gender, and history of never smoking (P = 0.0048 to <0.0001). 19706809 2009
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group LHGDN Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. 17046193 2007
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma. 17561234 2007
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker group BEFREE Combining 4 genes (CALCA, DAPK, ESR1 and APC) yielded a sensitivity of 89% (with all adenocarcinomas identified), equal to cytomorphology (89%) and high-risk human papilloma virus (Hr-HPV; 90%). 16736496 2006
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression group BEFREE Estrogen receptor (ER) alpha is expressed at low levels in normal epithelia, and its expression is dramatically up-regulated as transformation progresses during mammary hyperplasia and adenocarcinoma development. 17108100 2006